Literature DB >> 24737459

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.

Robert J Mentz1, Stephen J Greene1, Andrew P Ambrosy1, Muthiah Vaduganathan1, Haris P Subacius1, Karl Swedberg1, Aldo P Maggioni1, Savina Nodari1, Piotr Ponikowski1, Stefan D Anker1, Javed Butler1, Mihai Gheorghiade2.   

Abstract

BACKGROUND: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. METHODS AND
RESULTS: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin <12 g/dL for women and <13 g/dL for men) on admission or discharge/day 7. Overall, 1277 patients (34%) were anemic at baseline, which persisted through discharge in 73% and resolved in 27%; 6% of patients without baseline anemia developed anemia by discharge or day 7. Patients with anemia were older, with lower blood pressure, and higher creatinine and natriuretic peptide levels compared with those without anemia (all P<0.05). After risk adjustment, anemia at discharge, but not admission, was independently associated with increased all-cause mortality (hazard ratio, 1.30; 95% confidence interval, 1.05-1.60; P=0.015; and hazard ratio, 0.94; 95% confidence interval, 0.76-1.15; P=0.53, respectively) and cardiovascular mortality plus HF hospitalization early postdischarge (≤100 days; hazard ratio 1.73; 95% confidence interval, 1.37-2.18; P<0.001; and hazard ratio, 0.92; 95% confidence interval, 0.73-1.16; P=0.47, respectively). Neither baseline nor discharge anemia was associated with long-term cardiovascular mortality plus HF hospitalization (>100 days) on adjusted analysis (both P>0.1).
CONCLUSIONS: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  anemia; heart failure; hemoglobin; hospitalization

Mesh:

Substances:

Year:  2014        PMID: 24737459      PMCID: PMC4151504          DOI: 10.1161/CIRCHEARTFAILURE.113.000840

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  30 in total

Review 1.  Prevalence of anemia and effects on mortality in patients with heart failure.

Authors:  Joann Lindenfeld
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

2.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Authors:  Mihai Gheorghiade; Cesare Orlandi; John C Burnett; David Demets; Liliana Grinfeld; Aldo Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Christopher Zimmer; Marvin A Konstam
Journal:  J Card Fail       Date:  2005-05       Impact factor: 5.712

3.  Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project.

Authors:  Mikhail Kosiborod; Jeptha P Curtis; Yongfei Wang; Grace L Smith; Frederick A Masoudi; JoAnne M Foody; Edward P Havranek; Harlan M Krumholz
Journal:  Arch Intern Med       Date:  2005-10-24

4.  Anemia, physical disability, and survival in older patients with heart failure.

Authors:  Cinzia Maraldi; Stefano Volpato; Matteo Cesari; Graziano Onder; Claudio Pedone; Richard C Woodman; Renato Fellin; Marco Pahor
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

5.  Hemodilution is common in patients with advanced heart failure.

Authors:  Ana-Silvia Androne; Stuart D Katz; Lars Lund; John LaManca; Alhakam Hudaihed; Katarzyna Hryniewicz; Donna M Mancini
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

6.  Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones.

Authors:  I S Anand; Y Chandrashekhar; R Ferrari; P A Poole-Wilson; P C Harris
Journal:  Br Heart J       Date:  1993-10

7.  Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.

Authors:  G Michael Felker; Wendy A Gattis; Jeffrey D Leimberger; Kirkwood F Adams; Michael S Cuffe; Mihai Gheorghiade; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

8.  Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.

Authors:  Eileen O'Meara; Tim Clayton; Margaret B McEntegart; John J V McMurray; Chim C Lang; Simon D Roger; James B Young; Scott D Solomon; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric L Michelson; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

9.  Anemia and its relationship to clinical outcome in heart failure.

Authors:  Inder Anand; John J V McMurray; James Whitmore; Marshelle Warren; Anh Pham; Mark A McCamish; Paul B J Burton
Journal:  Circulation       Date:  2004-06-21       Impact factor: 29.690

10.  Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Authors:  Stephen J Greene; Mihai Gheorghiade; Muthiah Vaduganathan; Andrew P Ambrosy; Robert J Mentz; Haris Subacius; Aldo P Maggioni; Savina Nodari; Marvin A Konstam; Javed Butler; Gerasimos Filippatos
Journal:  Eur J Heart Fail       Date:  2013-07-11       Impact factor: 15.534

View more
  8 in total

Review 1.  Pathophysiology and clinical evaluation of acute heart failure.

Authors:  Robert J Mentz; Christopher M O'Connor
Journal:  Nat Rev Cardiol       Date:  2015-09-15       Impact factor: 32.419

2.  Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Ravi B Patel; Robert J Mentz; Haris Subacius; Neal A Chatterjee; Stephen J Greene; Andrew P Ambrosy; Aldo P Maggioni; James E Udelson; Karl Swedberg; Marvin A Konstam; Christopher M O'Connor; Javed Butler; Mihai Gheorghiade; Faiez Zannad
Journal:  Am J Cardiol       Date:  2018-04-11       Impact factor: 2.778

3.  Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure.

Authors:  Ovidiu Chioncel; Sean P Collins; Stephen J Greene; Peter S Pang; Andrew P Ambrosy; Elena-Laura Antohi; Muthiah Vaduganathan; Javed Butler; Mihai Gheorghiade
Journal:  Card Fail Rev       Date:  2017-11

Review 4.  Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.

Authors:  Evi V Nagler; Maria C Haller; Wim Van Biesen; Raymond Vanholder; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

5.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

6.  The prevalence and clinical significance of anemia in patients hospitalized with acute heart failure.

Authors:  Attila Frigy; Zoltán Fogarasi; Ildikó Kocsis; Lehel Máthé; Előd Nagy
Journal:  F1000Res       Date:  2016-05-26

7.  Anemia in severe heart failure patients: does it predict prognosis?

Authors:  Tamrat Befekadu Abebe; Eyob Alemayehu Gebreyohannes; Akshaya Srikanth Bhagavathula; Yonas Getaye Tefera; Tadesse Melaku Abegaz
Journal:  BMC Cardiovasc Disord       Date:  2017-09-16       Impact factor: 2.298

8.  Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction.

Authors:  Vera J Goh; Jasper Tromp; Tiew-Hwa K Teng; Wan Ting Tay; Peter Van Der Meer; Lieng Hsi Ling; Bambang B Siswanto; Chung-Lieh Hung; Wataru Shimizu; Shu Zhang; Calambur Narasimhan; Cheuk Man Yu; Sang Weon Park; Tachapong Ngarmukos; Houng Bang Liew; Eugenio Reyes; Jonathan Yap; Michael MacDonald; Mark A Richards; Inder Anand; Carolyn S P Lam
Journal:  ESC Heart Fail       Date:  2018-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.